Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
information fournie par Boursorama CP 28/06/2022 à 08:00

Strasbourg, France, and Lund, Sweden, June 28, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

Under the terms of the supply agreement, MSD will provide pembrolizumab to be used in combination with BT-001 in the ongoing Phase I/IIa clinical trial.

.../...

Valeurs associées

TRANSGENE
0,7690 EUR Euronext Paris -0,13%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
SPACEX
161,37 +19,53%
Pétrole Brent
86,88 -2,52%
CAC 40
8 350,87 +1,83%
SOITEC
137,35 +6,80%
HAFFNER ENERGY
0,2755 +11,76%
Chargement...

Pages les plus populaires

L'offre BoursoBank